MACOM (MTSI) stock slips into next week as chip jitters return and Feb. 5 earnings loom

MACOM (MTSI) stock slips into next week as chip jitters return and Feb. 5 earnings loom

New York, January 24, 2026, 21:16 (EST) — The market has closed.

  • Shares of MACOM Technology Solutions Holdings, Inc. slipped 2.3%, ending Friday at $219.26.
  • MACOM Technology Solutions will release its first-quarter results on Feb. 5 ahead of market open, with a conference call scheduled for 8:30 a.m. ET. 1

MACOM Technology Solutions kicks off the week with its upcoming earnings report as the chip sector shows fresh signs of volatility.

The pullback is crucial now, with the coming days loaded with events that could jolt semiconductor stocks: major U.S. tech earnings reports, a Federal Reserve meeting, and for MACOM, a results announcement that will clarify demand trends in data center and telecom sectors.

Friday’s late-week vibe showed up in the tape. “We feel pretty good about where we are today,” said Jason Blackwell, chief investment strategist at Focus Partners Wealth. But Janus Henderson portfolio manager Julian McManus cautioned the market’s in a “show-me” phase, where companies need to “put up the revenue growth.” 2

MACOM announced it will report its first-quarter results for the period ending Jan. 2 ahead of the U.S. market open on Thursday, Feb. 5. CEO Stephen G. Daly and CFO John F. Kober will lead the conference call, the company confirmed. 3

On Friday, the Dow dropped 0.58%, while the Nasdaq gained 0.28%. Intel’s shares slipped after it projected quarterly revenue and earnings below expectations, also revealing challenges in meeting demand for server chips powering AI data centers. 2

Other chip-related stocks closed the week down. Broadcom declined 1.7%, Marvell slipped 3.5%, Lumentum dropped 4.4%, and Coherent fell 2.9%.

MACOM develops and manufactures semiconductor products for industrial, defense, data center, and telecommunications sectors, according to its company profile. 4

Traders are zeroing in on the Feb. 5 report less for the past quarter’s numbers and more for clues about the quarter ahead. Shifts in commentary on data-center connectivity, telecom spending, or order flow could move the needle, especially as sentiment in the sector has grown more cautious.

The downside is straightforward: a cautious outlook or even a whisper that customers are slowing orders can slam the sector. Investors have already priced in growth, and macro headlines can turn risk appetite on a dime.

The market’s next focal point is the Fed meeting on Jan. 27–28, with the policy decision set for Jan. 28. After that, investors will turn to MACOM’s results and guidance due Feb. 5. 5

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Qatar Airways boosts South Africa flights to 42 a week — what changes for Cape Town, Johannesburg and Durban
Previous Story

Qatar Airways boosts South Africa flights to 42 a week — what changes for Cape Town, Johannesburg and Durban

VeriSilicon (688521.SH) stock set for Monday test after 2025 forecast flags AI-order jump
Next Story

VeriSilicon (688521.SH) stock set for Monday test after 2025 forecast flags AI-order jump

Go toTop